Risk factors

Silo Pharma added numerous risks regarding a new cryptocurrency treasury strategy, including regulatory classification, staking, and custody. Share counts and warrant overhang shifted significantly, with warrant counts rising from 2.2 million to 10.2 million.

The Trust added operational, accounting, and tax risks while updating operator recovery timelines and tax legislation references.

Cash dropped to $16.4M in 2025, threatening operations.

The main risks are failing to complete a business combination by the January 8, 2028 deadline and needing shareholder-approved extensions.

Soulpower Acquisition Corp. is a blank check company seeking its initial business combination, currently evaluating a potential deal with SWB. Key risks include heavy dilution from initial shareholders, potential redemption constraints, and operating without a specific industry focus or management expertise limits.

Office properties generated 58% of net operating income in 2025, down from 65% in 2024. Commercial mortgage payments total $25.5 million for 2026. Nasdaq granted an extension until June 2, 2025, to regain minimum bid price compliance.

The company is a newly formed blank check entity focusing on completing an initial business combination.

Instil Bio shifted from clinical-stage oncology to an acquirer of early-stage assets after discontinuing multiple programs and workforce reductions.

Talon Capital Corp. is a blank check company with $249,000,000 in a trust account seeking an initial business combination. Risks center on shareholder redemption rights, potential conflicts of interest among officers, and the lack of a target business.

The key structural risk is failing to complete a business combination by February 12, 2028, potentially requiring an extension and shareholder redemptions.

Tenon Medical added risks regarding trade policy and tariffs, product modifications requiring 510(k) clearance, stock delisting fears, and internal controls weaknesses.

Regulatory demands and healthcare bureaucracy threaten UTMD’s costs, revenue, management focus, and competitive position as a small device maker.